<DOC>
	<DOCNO>NCT02004366</DOCNO>
	<brief_summary>A total 280 patient type 2 diabetes ( T2DM ) undergone surgical procedure enrol study . These patient could diet , oral hypoglycemia medication low dose insulin prior admission . This study prospective , randomize , open label trial compare safety efficacy linagliptin ( oral anti diabetic medication ) give orally daily insulin regimen glargine daily plus rapid-acting insulin meal . Both treatment group give corrective dos rapid-acting insulin analog ( aspart , lispro glulisine ) meal blood sugar &gt; 140 mg/dl . The patient monitor blood sugar hospital . If patient agreeable participate discharge part study , investigator randomize treatment group base admission HbA1c . The investigator follow patient 3 month phone call clinic visit , monitor blood sugar . This compare efficacy linagliptin discharge treatment algorithm control blood sugar patient .</brief_summary>
	<brief_title>Linagliptin Inpatient Trial</brief_title>
	<detailed_description>Specific Aim 1 : To determine whether in-hospital glycemic control , measure mean daily glucose concentration frequency hypoglycemic event , different treatment linagliptin ( Tradjenta® ) plus correction dose rapid-acting insulin analog meal basal bolus regimen glargine daily rapid-acting insulin analog meal general surgery patient T2D . Specific Aim 2 : To determine efficacy safety A1C base discharge algorithm control BG discharge patient T2D . Patients participate in-hospital arm ( Aim 1 ) invite enroll open label prospective outpatient study . The total duration study 3 month .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>1 . Males female surgical nonICU patient age between18 80 year 2 . A known history T2D &gt; 1 month , receive either diet alone , oral antidiabetic agent : sulfonylurea metformin monotherapy combination therapy ( exclude DPP4 inhibitor ) lowdose ( ≤ 0.5 units/kg/day ) insulin therapy . 3 . Subjects BG &gt; 140 mg &lt; 400 mg/dL time randomization without laboratory evidence diabetic ketoacidosis ( serum bicarbonate &lt; 18 mEq/L positive serum urinary ketone ) 1 . Age &lt; 18 &gt; 80 year . 2 . Subjects increase BG concentration , without history diabetes ( stress hyperglycemia ) . 3 . Subjects history type 1 diabetes ( suggest BMI &lt; 25 require insulin therapy history diabetic ketoacidosis hyperosmolar hyperglycemic state , ketonuria ) ( 43 ) . 4 . Treatment dipeptidyl peptidase4 ( DPP4 ) inhibitor Glucagonlike peptide1 ( GLP1 ) analogs past 3 month prior admission . 5 . Acute critical illness coronary artery bypass graft ( CABG ) surgery expect require admission critical care unit . 6 . Subjects gastrointestinal obstruction adynamic ileus expect require gastrointestinal suction . 7 . Patients clinically relevant pancreatic gallbladder disease . 8 . Patients previous history pancreatitis 9 . Patients acute myocardial infarction , clinically significant hepatic disease significantly impair renal function ( GFR &lt; 30 ml/min ) . 10 . Chronic use steroid total daily dose ( prednisone equivalent ) &gt; 5 mg/day 11 . Mental condition render subject unable understand nature , scope , possible consequence study . 12 . Pregnancy breast feeding time enrollment study . 13 . Patients receive supplemental slide scale insulin &gt; 72 hour prior randomization 14 . Patients receive basal insulin &gt; 48 hour prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Linagliptin</keyword>
	<keyword>hospital hyperglycemia</keyword>
	<keyword>inpatient diabetes</keyword>
</DOC>